Careside Inc (NASDAQ:CASI) Move as Institutional Investors’ Sentiment Increased

May 26, 2018 - By Henry Gaston

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Logo

Sentiment for Careside Inc (NASDAQ:CASI)

Careside Inc (NASDAQ:CASI) institutional sentiment increased to 1.9 in 2017 Q4. Its up 0.76, from 1.14 in 2017Q3. The ratio is better, as 19 institutional investors opened new or increased equity positions, while 10 sold and decreased their positions in Careside Inc. The institutional investors in our partner’s database now possess: 3.56 million shares, up from 2.39 million shares in 2017Q3. Also, the number of institutional investors holding Careside Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 7 Increased: 8 New Position: 11.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $584.93 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

The stock decreased 2.72% or $0.19 during the last trading session, reaching $6.79. About 189,978 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 181.56% since May 26, 2017 and is uptrending. It has outperformed by 170.01% the S&P500.

Wellington Shields & Co. Llc holds 0.78% of its portfolio in CASI Pharmaceuticals, Inc. for 445,118 shares. Wellington Shields Capital Management Llc owns 725,348 shares or 0.37% of their US portfolio. Moreover, Alpine Global Management Llc has 0.02% invested in the company for 27,729 shares. The Massachusetts-based Moors & Cabot Inc. has invested 0.01% in the stock. Perceptive Advisors Llc, a New York-based fund reported 83,682 shares.

More important recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: Nasdaq.com which released: “Can These Top-Performing Biotech Stocks Keep Climbing?” on April 30, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss”, Nasdaq.com published: “Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress …” on May 07, 2018. More interesting news about CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was released by: Prnewswire.com and their article: “CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results” with publication date: May 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.